Puration Inc. (PURA: OTC Pink Current) | Spanish Peaks Confirms Puration Million Dollar Cannabis Infused Beverage Collaboration Agreement and Issues Update On Beverage Production


Spanish Peaks Confirms Puration Million Dollar Cannabis Infused Beverage Collaboration Agreement and Issues Update On Beverage Production

Dec 29, 2016

OTC Disclosure News Service

Dallas, TX

Dallas, Texas – December 29, 2016 –
Puration, Inc. (PURA) today released a confirmation and update regarding its $1
million collaboration agreement with Spanish Peaks ScrumpDelicacies.  Earlier this year, PURA and Spanish
Peaks entered into a collaboration agreement to produce a line of cannabis
Infused beverages.  In conjunction
with the agreement, Spanish Peaks conducted a cannabis beverage naming contest
and announced the contest winners on October 21, 2016:


and Spanish Peaks Announce Cannabis Beverage Name Contest Winners – First
CannaCola Second CannaBliss and Third Canna Pur


Since the contest, Spanish Peaks
has worked to establish brand name trademarks and to develop beverage
formulations.  Spanish Peaks
reports that progress has been slower than anticipated
due to the unfortunate and very unexpected passing of a senior Spanish Peaks
partner and manager.  Today,
Spanish Peaks is happy to announce that the Company has made some exciting new
progress anticipated to not only get the beverage production process back on
track, but to add some exciting new features to the business plan.  The new progress is expected to have a
very positive impact on the existing collaboration agreement with PURA.  Look for details on the new progress
coming soon.


To learn more about Puration:                                                 purationinc.com
Follow Puration on Twitter:                                                             Puration710
Visit Puration on Facebook:                                                             Facebook.com/puration/


Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform Act. The
statements reflect the Company’s current views with respect to future events
that involve risks and uncertainties. Among others, these risks include the
expectation that Alkame will achieve significant sales, the failure to meet schedule
or performance requirements of the Company’s contracts, the Company’s liquidity
position, the Company’s ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of competitive
pricing. In the light of these uncertainties, the forward-looking events
referred to in this release might not occur. These statements have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.


Puration Contact:

Brian Shibley, CEO


Copyright © 2016 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply